This could be due to timing—D8 patient samples (blood and TIL) were taken prior to the peak in immune activation—or the tumor microenvironment in these tumors was more suppressive and prevented infiltration and/or expansion of CD103+ CD39+ CD8+ TIL. The gene discussed is ITGAE; the disease is neoplasm.